Resumen

FERREIRA, Sandra; FERNANDES, Iolanda; CABRAL, Renata  y  LIMA, Margarida. Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases. Rev Soc Port Dermatol Venereol [online]. 2021, vol.79, n.1, pp.42-45.  Epub 15-Jun-2021. ISSN 2182-2395.  https://doi.org/10.29021/spdv.79.1.1277.

Brentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies.

Palabras clave : Brentuximab Vedotin; Lymphoma, Primary Cutaneous Anaplastic Large Cell/ drug therapy; Lymphoma, T-Cell, Cutaneous/drug therapy; Skin Neoplasms/ drug therapy.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )